
Editor’s Choice

MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study
MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage clinical-stage biotechnology company leading the development of Microbiome Ecosystem Therapies TM (MET) to improve survival in cancer patients through modulation of the immune system, today announced topline results from […]

Lallemand’s New R&D Laboratories: An Exclusive Interview with Sylvie Binda, VP of R&D
Following the announcement of Lallemand’s new R&D laboratories in France, Microbiome Times caught up with Sylvie Binda, VP of R&D to discuss the company’s goals and objectives. Can you elaborate on how the new laboratories […]

Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims
Eczema and Atopic Dermatitis (AD) is thought to affect as many as 10% of adults worldwide and represents a debilitating condition for many.1 It can result in a lower quality of life, and reports link […]
In Case you Missed it:

MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study
MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage clinical-stage biotechnology company leading the development of Microbiome Ecosystem Therapies TM (MET) to improve survival in cancer patients through modulation of the immune system, today announced topline results from […]

A new way to determine whether a species will successfully invade an ecosystem
When a new species is introduced into an ecosystem, it may succeed in establishing itself, or it may fail to gain a foothold and die out. Physicists at MIT have now devised a formula that […]

Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics
Antibiotics are important clinical tools for treating bacterial infections, yet we recognize that an important side effect of antibiotic use is disruption of the microbial community living in the human gut. Antibiotics targeted against bacterial […]

Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer
Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the […]

Possible colon cancer vaccine target uncovered in bacteria
Higher rates of certain cancers in countries, such as the UK, may be linked to two particular strains of bacteria. Targeting these with treatments or vaccines could help reduce the risk of colorectal, bladder, and […]

SNIPR Biome receives up to €20 million European backing to advance therapies AMR
Danish biotech SNIPR Biome will get up to €20 venture debt from the European Investment Bank (EIB) to step up Europe’s fight against antimicrobial resistance to medicines. The company will use the EIB credit to […]

UCalgary startup Taylored Biotherapeutics to commercialize psychobiotic therapies
Taylored Biotherapeutics, founded by UCalgary’s Dr. Valerie Taylor, MD, PhD, and supported by Chief Operating Officer Asem Bala, has achieved a significant milestone by securing a $100,000 grant from the Ontario Brain Institute (OBI). This award, part of OBI’s highly competitive Neurotech […]

A new simple and effective tool that recommends the best possible phage cocktail for a given patient
With the rapid development of antibiotics in the 1930s, phage therapy – using viruses known as bacteriophages or phages to tackle bacterial infections – fell into oblivion. But as the current rise in antibiotic resistance […]